{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-109069","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.087986+00:00","generated_at":"2026-05-31T02:05:36.342902+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings","bullets":["Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.","One-time severance costs of approximately $2 million expected in Q3 2024.","Annual operating expense savings of about $10 million anticipated starting Q1 2025.","Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-109069","json":"https://secwatch.observer/filing/0000950170-24-109069.json","markdown":"https://secwatch.observer/filing/0000950170-24-109069.md","text":"https://secwatch.observer/filing/0000950170-24-109069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024109069/0000950170-24-109069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024109069/fulc-20240924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:05:36.342902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}